Lupin launches Luforbec 100/6 for COPD treatment in Germany

First-ever product launch in the inhalation segment in Germany

Hormosan Pharma GmbH (Hormosan), Lupin’s wholly-owned subsidiary in Germany, announced the launch of Luforbec 100/6 (beclometasone 100 µg / formoterol 6 µg), a fix combination in a pressurised metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.

Luforbec 100µg/6µg pMDI is indicated for adult asthma and COPD treatment, where the use of an inhaled corticosteroid and long-acting beta₂-agonist (ICS/LABA) is suitable. With the same active ingredients as Foster 100/6 pMDI and an extra fine formulation, Luforbec offers the same licensed indications and similar device characteristics. Luforbec pMDI provide significant cost savings, priced at – 47 per cent below the fixed reference price on the pharmacy selling price.

Anjan Selz, Managing Director, Hormosan Pharma GmbH, added, “The launch of Luforbec 100/6 pMDI in Germany represents a significant milestone in our goal to establish Hormosan as a key player in the inhalation segment. We are committed to improving healthcare outcomes by ensuring the accessibility and affordability of reliable and comprehensive solutions for patients and healthcare professionals. This launch reinforces our dedication to making asthma and COPD management more accessible for the German population.”